Land: USA
Språk: engelska
Källa: NLM (National Library of Medicine)
GLIMEPIRIDE (UNII: 6KY687524K) (GLIMEPIRIDE - UNII:6KY687524K)
Dr. Reddy's Laboratories Limited
GLIMEPIRIDE
GLIMEPIRIDE 1 mg
ORAL
PRESCRIPTION DRUG
Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1) ]. Limitations of Use Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. Glimepiride tablets are contraindicated in patients with a history of a hypersensitivity reaction to: - Glimepiride or any of the product’s ingredients [see Warnings and Precautions (5.2) ]. - Sulfonamide derivatives: Patients who have developed an allergic reaction to sulfonamide derivatives may develop an allergic reaction to glimepiride. Do not use glimepiride in patients who have a history of an allergic reaction to sulfonamide derivatives. Risk Summary Available data from a small number of published studies and postmarketing experience with glimepiride use in pregnancy over decades have not identified any drug associated risks for major birth defects, miscarria
Glimepiride tablets USP, are available in the following strengths and package sizes: Glimepiride tablets USP, 1 mg are peach, oval, flat beveled edged, uncoated tablets debossed “RDY” on one side and “320” separating “3” and “20” with bisect line scoring on the other side and are supplied in bottles of 30, 100, 500 and unit dose package of 100 (10 x 10). Bottles of 30 NDC 55111-320-30 Bottles of 100 NDC 55111-320-01 Bottles of 500 NDC 55111-320-05 Unit dose package of 100 (10 x 10) NDC 55111-320-78 Glimepiride tablets USP, 2 mg are green, oval, flat beveled edged, uncoated tablets debossed “RDY” on one side and “321” separating “3” and “21” with bisect line scoring on the other side and are supplied in bottles of 30, 100, 500 and unit dose package of 100 (10 x 10). Bottles of 30 NDC 55111-321-30 Bottles of 100 NDC 55111-321-01 Bottles of 500 NDC 55111-321-05 Unit dose package of 100 (10 x 10) NDC 55111-321-78 Glimepiride tablets USP, 4 mg are blue, oval, flat beveled edged, uncoated tablets debossed “RDY” on one side and “322” separating “3” and “22” with bisect line scoring on the other side and are supplied in bottles of 30, 100, 500 and unit dose package of 100 (10 x 10). Bottles of 30 NDC 55111-322-30 Bottles of 100 NDC 55111-322-01 Bottles of 500 NDC 55111-322-05 Unit dose package of 100 (10 x 10) NDC 55111-322-78 Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Dispense in well-closed containers with safety closures.
Abbreviated New Drug Application
GLIMEPIRIDE- GLIMEPIRIDE TABLET DR. REDDY'S LABORATORIES LIMITED ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE GLIMEPIRIDE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR GLIMEPIRIDE TABLETS. GLIMEPIRIDE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1995 INDICATIONS AND USAGE Glimepiride tablets are a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1). Limitations of Use: Not for treating type 1 diabetes mellitus or diabetic ketoacidosis (1). DOSAGE AND ADMINISTRATION Recommended starting dose is 1 or 2 mg once daily. Increase in 1 or 2 mg increments no more frequently than every 1 to 2 weeks based on glycemic response. Maximum recommended dose is 8 mg once daily. (2.1) Administer with breakfast or first meal of the day. (2.1) Use 1 mg starting dose and titrate slowly in patients at increased risk for hypoglycemia (e.g., elderly, patients with renal impairment). (2.1) DOSAGE FORMS AND STRENGTHS Tablets (scored): 1 mg, 2 mg, 4 mg (3) (3) CONTRAINDICATIONS Hypersensitivity to glimepiride or any of the product’s ingredients (4) Hypersensitivity to sulfonamide derivatives (4) WARNINGS AND PRECAUTIONS Hypoglycemia: May be severe. Ensure proper patient selection, dosing, and instructions, particularly in at-risk populations (e.g., elderly, renally impaired) and when used with other anti-diabetic medications (5.1). Hypersensitivity Reactions: Postmarketing reports include anaphylaxis, angioedema and Stevens-Johnson Syndrome. If a reaction is suspected, promptly discontinue glimepiride, assess for other potential causes for the reaction, and institute alternative treatment for diabetes (5.2). Hemolytic Anemia: Can occur if glucose 6-phosphate dehydrogenase (G6PD) deficient. Consider a non-sulfonylurea alternative. (5.3) Potential Increased Risk of Cardiovascular Mortality with Sulfonylureas: Inform patient of risks, benefits and treatment alternatives (5 Läs hela dokumentet